. 2021 Oct 9;361:577746. doi: 10.1016/j.jneuroim.2021.577746

Table 2.

Humoral immune response following COVID-19 vaccination in MS patients.

Mean ± SD Median (95% CI) Range	Time from 2nd vaccine dose, days	SARS-COV-2 IgG Index	SARS-COV-2 positive N, %	ALC cells/mm³	Time from last dosing, months
Healthy	89.9 ± 39.3 75.0 (81.7–98.2) 28–165	6.7 ± 1.9 7.1 (6.2–7.1) 0.2–10.1	87/89 97.8	2090 ± 812 2130 1747–2432 840–4020	_____
N = 89	89.9 ± 39.3 75.0 (81.7–98.2) 28–165	6.7 ± 1.9 7.1 (6.2–7.1) 0.2–10.1	87/89 97.8	2090 ± 812 2130 1747–2432 840–4020	_____
Untreated MS	89.4 ± 39.9 77.0 (80.3–98.5) 28–167	7.3 ± 1.6 7.9 (9.5–14.7) 2.3–9.3	76/76 100	2378 ± 1418 2100 (2002–2755) 580–8480	_____
N = 76, 18.4%	89.4 ± 39.9 77.0 (80.3–98.5) 28–167	7.3 ± 1.6 7.9 (9.5–14.7) 2.3–9.3	76/76 100	2378 ± 1418 2100 (2002–2755) 580–8480	_____
Alemtuzumab	85.8 ± 42.0 73.5 (67.1–104.4) 28–171	7.0 ± 2.9 7.9 (5.7–8.3) 0–9.3	19/22 86.4	1215 ± 348 1085 (1051–1378) 800–2080	21.6 ± 13.7 17.4 (14.3–28.9) 3.6–50.1
N = 22	85.8 ± 42.0 73.5 (67.1–104.4) 28–171	7.0 ± 2.9 7.9 (5.7–8.3) 0–9.3	19/22 86.4	1215 ± 348 1085 (1051–1378) 800–2080	21.6 ± 13.7 17.4 (14.3–28.9) 3.6–50.1
Cladribine	89.3 ± 42.8 66.5 (76.9–101.7) 33–167	6.3 ± 1.9 6.6 (5.7–6.8) 1.9–9.4	48/48 100	1029 ± 390 950 (916–1142) 440–1930	8.5 ± 4.8 6.8 (7.1–9.9) 2.8–22.6
N = 48	89.3 ± 42.8 66.5 (76.9–101.7) 33–167	6.3 ± 1.9 6.6 (5.7–6.8) 1.9–9.4	48/48 100	1029 ± 390 950 (916–1142) 440–1930	8.5 ± 4.8 6.8 (7.1–9.9) 2.8–22.6
Dimethyl fumarate	76.4 ± 29.4 64.0 (66.3–86.5) 43.0–169.0	7.5 ± 1.2 7.6 (7.1–7.9) 4.4–9.3	35/35 100	1505 ± 559 1390 (1303–1707) 830–2900	_____
N = 35	76.4 ± 29.4 64.0 (66.3–86.5) 43.0–169.0	7.5 ± 1.2 7.6 (7.1–7.9) 4.4–9.3	35/35 100	1505 ± 559 1390 (1303–1707) 830–2900	_____
Fingolimod	88.0 ± 39.5 76.0 (75.7–100.4) 28–175	0.5 ± 0.7 0.3 (0.3–0.7) 0–3.2	4/42 9.5	606 ± 227 600 (535–677) 270–1220	_____
N = 42	88.0 ± 39.5 76.0 (75.7–100.4) 28–175	0.5 ± 0.7 0.3 (0.3–0.7) 0–3.2	4/42 9.5	606 ± 227 600 (535–677) 270–1220	_____
Natalizumab	69.1 ± 30.4 63.0 (58.1–80.1) 28–172	7.2 ± 1.7 7.4 (6.6–7.8) 1.7–9.1	32/32 100	3562 ± 1333 3630 (3081–4042) 900–6130	_____
N = 32	69.1 ± 30.4 63.0 (58.1–80.1) 28–172	7.2 ± 1.7 7.4 (6.6–7.8) 1.7–9.1	32/32 100	3562 ± 1333 3630 (3081–4042) 900–6130	_____
Ocrelizumab	87.4 ± 37.2 70.0 (80.5–94.3) 48–169	0.9 ± 1.5 0.2 (0.6–1.2) 0.0–7.4	26/114 22.8	1834 ± 641 1750 (1714–1953) 850–4650	4.3 ± 1.8 4.1 4.0–4.6 1.0–12.0
N = 114	87.4 ± 37.2 70.0 (80.5–94.3) 48–169	0.9 ± 1.5 0.2 (0.6–1.2) 0.0–7.4	26/114 22.8	1834 ± 641 1750 (1714–1953) 850–4650	4.3 ± 1.8 4.1 4.0–4.6 1.0–12.0
Rituximab	100 ± 46.5 110.5 (51.2–148.8) 28–155	2.3 ± 2.8 0.8 (−0.7–5.2) 0.1–6.7	2/6 33	1405 ± 316 1285 (1072–1737) 1150–1890	29.2 ± 25.2 16.4 (−33.4–91.7) 12.9–58.2
N = 6	100 ± 46.5 110.5 (51.2–148.8) 28–155	2.3 ± 2.8 0.8 (−0.7–5.2) 0.1–6.7	2/6 33	1405 ± 316 1285 (1072–1737) 1150–1890	29.2 ± 25.2 16.4 (−33.4–91.7) 12.9–58.2
Teriflunomide	91.6 ± 40.9 71.0 (78.3–104.9) 35–161	6.6 ± 1.6 6.8 (6.1–7.2) 2.6–9.3	39/39 100	1666 ± 551 1580 (1464–1868) 870–3470	_____
N = 39	91.6 ± 40.9 71.0 (78.3–104.9) 35–161	6.6 ± 1.6 6.8 (6.1–7.2) 2.6–9.3	39/39 100	1666 ± 551 1580 (1464–1868) 870–3470	_____

*Time from 2nd vaccine dose (days) and Time from last treatment dosing (months) were calculated as the time difference to the date of SARS-COV-2 IgG test.